CPIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-30), Cumberland Pharmaceuticals's current share price is $1.695. Cumberland Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.18. Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 9.42.
The historical rank and industry rank for Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Cumberland Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 162.50. The lowest was 8.89. And the median was 41.86.
CPIX's Cyclically Adjusted Price-to-FCF is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Cumberland Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.067. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.18 for the trailing ten years ended in Dec. 2023.
The historical data trend for Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 24.77 | 25.30 | 12.40 | 13.55 | 9.82 |
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 1.695 | / | 0.18 | |
= | 9.42 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Cumberland Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.067 | / | 129.4194 | * | 129.4194 | |
= | 0.067 |
Current CPI (Dec. 2023) = 129.4194.
Cumberland Pharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | 0.031 | 99.695 | 0.040 |
201406 | 0.026 | 100.560 | 0.033 |
201409 | 0.064 | 100.428 | 0.082 |
201412 | 0.070 | 99.070 | 0.091 |
201503 | -0.008 | 99.621 | -0.010 |
201506 | 0.082 | 100.684 | 0.105 |
201509 | 0.047 | 100.392 | 0.061 |
201512 | 0.066 | 99.792 | 0.086 |
201603 | -0.006 | 100.470 | -0.008 |
201606 | -0.098 | 101.688 | -0.125 |
201609 | -0.013 | 101.861 | -0.017 |
201612 | 0.021 | 101.863 | 0.027 |
201703 | 0.054 | 102.862 | 0.068 |
201706 | -0.178 | 103.349 | -0.223 |
201709 | 0.055 | 104.136 | 0.068 |
201712 | -0.059 | 104.011 | -0.073 |
201803 | -0.025 | 105.290 | -0.031 |
201806 | 0.044 | 106.317 | 0.054 |
201809 | -0.160 | 106.507 | -0.194 |
201812 | 0.066 | 105.998 | 0.081 |
201903 | -0.049 | 107.251 | -0.059 |
201906 | 0.113 | 108.070 | 0.135 |
201909 | 0.036 | 108.329 | 0.043 |
201912 | 0.033 | 108.420 | 0.039 |
202003 | 0.020 | 108.902 | 0.024 |
202006 | 0.172 | 108.767 | 0.205 |
202009 | -0.018 | 109.815 | -0.021 |
202012 | 0.043 | 109.897 | 0.051 |
202103 | 0.109 | 111.754 | 0.126 |
202106 | 0.175 | 114.631 | 0.198 |
202109 | -0.014 | 115.734 | -0.016 |
202112 | 0.127 | 117.630 | 0.140 |
202203 | -0.013 | 121.301 | -0.014 |
202206 | 0.147 | 125.017 | 0.152 |
202209 | 0.167 | 125.227 | 0.173 |
202212 | 0.139 | 125.222 | 0.144 |
202303 | -0.109 | 127.348 | -0.111 |
202306 | 0.353 | 128.729 | 0.355 |
202309 | 0.080 | 129.860 | 0.080 |
202312 | 0.067 | 129.419 | 0.067 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd M. Anthony | officer: Vice Pres Organizational Dev | 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203 |
Chris T. Bitterman | officer: Vice Pres Sales & Marketing | 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203 |
Joseph C Galante | director | 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203 |
James Jones | director | 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203 |
Kenneth Krogulski | director | 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
Caroline Young | director | 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
Brown Martin S Jr | director | 850 DIXIE HIGHWAY, LOUISVILLE KY 40210 |
A J Kazimi | director, 10 percent owner, officer: Chairman and CEO | 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212 |
Martin E Cearnal | director | 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042 |
John M. Hamm | officer: Chief Financial Officer | 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
Gordon R Bernard | officer: Senior Vice President | 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
Joey A Jacobs | director | 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067 |
Michael Bonner | officer: Chief Financial Officer | 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
Jonathan Griggs | director | 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
Thomas R Lawrence | director | 1880 ELLINGTON WAY, AUBURN AL 36830 |
From GuruFocus
By PRNewswire PRNewswire • 11-01-2022
By PRNewswire PRNewswire • 06-18-2022
By PRNewswire PRNewswire • 08-08-2022
By PRNewswire PRNewswire • 03-01-2022
By PRNewswire PRNewswire • 11-01-2022
By PRNewswire PRNewswire • 08-03-2021
By PRNewswire PRNewswire • 07-08-2022
By PRNewswire PRNewswire • 05-29-2022
By PRNewswire PRNewswire • 06-28-2022
By PRNewswire PRNewswire • 05-09-2022